For users who are already overwhelmed by managing their GLP-1 dosing protocol , the simplicity of Replenza has real value
In people with DKD, the once-weekly GLP-1 receptor agonist dulaglutide increased mGFR (37), although semaglutide appeared to initially reduce eGFR (15)
Slowing the climb is the main lever
Complete prevention is not guaranteed, but you can significantly reduce your risk and severity
This is a problem we call the Quality-Price Gap. We put Hers under the microscope to see how it measures up on safety, cost, and long-term support, helping you bridge the gap between safety and affordability
Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial